- Home
- DBRG vs HCM Comparison
DBRG vs HCM Comparison
Compare DBRG & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBRG
- HCM
- Stock Information
- Founded
- DBRG 1991
- HCM 2000
- Country
- DBRG United States
- HCM Hong Kong
- Employees
- DBRG N/A
- HCM N/A
- Industry
- DBRG Real Estate Investment Trusts
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- DBRG Real Estate
- HCM Health Care
- Exchange
- DBRG Nasdaq
- HCM Nasdaq
- Market Cap
- DBRG 2.0B
- HCM 2.3B
- IPO Year
- DBRG 2009
- HCM N/A
- Fundamental
- Price
- DBRG $12.15
- HCM $16.11
- Analyst Decision
- DBRG Strong Buy
- HCM Hold
- Analyst Count
- DBRG 9
- HCM 1
- Target Price
- DBRG $16.67
- HCM $19.00
- AVG Volume (30 Days)
- DBRG 2.6M
- HCM 73.5K
- Earning Date
- DBRG 02-20-2025
- HCM 03-19-2025
- Dividend Yield
- DBRG 0.33%
- HCM N/A
- EPS Growth
- DBRG N/A
- HCM N/A
- EPS
- DBRG 0.07
- HCM N/A
- Revenue
- DBRG $607,028,000.00
- HCM $610,806,000.00
- Revenue This Year
- DBRG N/A
- HCM N/A
- Revenue Next Year
- DBRG N/A
- HCM $15.89
- P/E Ratio
- DBRG $67.56
- HCM N/A
- Revenue Growth
- DBRG N/A
- HCM N/A
- 52 Week Low
- DBRG $10.04
- HCM $12.84
- 52 Week High
- DBRG $19.49
- HCM $21.92
- Technical
- Relative Strength Index (RSI)
- DBRG 65.50
- HCM 68.69
- Support Level
- DBRG $10.04
- HCM $13.58
- Resistance Level
- DBRG $12.63
- HCM $13.96
- Average True Range (ATR)
- DBRG 0.56
- HCM 0.31
- MACD
- DBRG 0.19
- HCM 0.34
- Stochastic Oscillator
- DBRG 81.50
- HCM 89.84
About DBRG DigitalBridge Group Inc.
DigitalBridge Group Inc is a developer of alternative asset manager dedicated to investing in digital infrastructure. The company's platform invests in and operates businesses across the digital ecosystem, including cell towers, data centers, fiber, small cells, and edge infrastructure, to provide clients with funds for digital infrastructure real estate infrastructure.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.